Article
A pan‐cancer analysis identifies HDAC11 as an immunological and prognostic biomarker
3 Jun 2022
Abstract excerpt
Histone deacetylase 11 (HDAC11) is aberrantly expressed in many types of cancer, and such abnormalities are associated with tumor immunity and heterogeneous clinical outcomes. Here, we explore the prognostic value and immunological function of HDAC11 across 33 cancer types. We observe HDAC11 is aberrantly expressed in 25 cancer types and positively or negatively associated with prognosis in different cancers....
Topics
Join the communities discussing this publication.